Trial site
Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
Istanbul, 34722, TürkiyeNot linked to an institution yet
- 15running trials
- 2closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 23 trials
- Phase 1/21 trial
- Status
- Active, not recruiting13 trials
- Completed2 trials
- Recruiting2 trials
- Lead sponsor
- Amgen9 trials
- Janssen Research & Development, LLC4 trials
- BioNTech SE2 trials
- IO Biotech1 trial
- Janssen Pharmaceutica N.V., Belgium1 trial
Running trials
Active, not recruiting
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128· Phase 3· Amgen· Source
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433· Phase 3· Amgen· Source
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459· Phase 3· Amgen· Source
Active, not recruiting
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
NCT06745323· Phase 2· Amgen· Source
Active, not recruiting
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222· Phase 2· BioNTech SE· Source
Active, not recruiting
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
NCT06449209· Phase 2· BioNTech SE· Source
Active, not recruiting
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774· Phase 3· Amgen· Source
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356· Phase 3· Amgen· Source
Active, not recruiting
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566· Phase 3· Amgen· Source
Active, not recruiting
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
NCT05908734· Phase 1/2· Janssen Research & Development, LLC· Source
Active, not recruiting
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
NCT05155254· Phase 3· IO Biotech· Source
Active, not recruiting
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
NCT04557059· Phase 3· Janssen Pharmaceutica N.V., Belgium· Source
Active, not recruiting
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641· Phase 3· Janssen Research & Development, LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error